It sounds like you are contemplating getting API direct from somewhere.

Please be aware there is a lot to know that you probably don’t, but to answer the question directly you are looking for:

Sofosbuvir CAS 1190307-88-0
Daclatasvir 2HCl CAS 1009119-65-6
Ledipasvir Acetone CAS 1441674-54-9

Please note that Sofosbuvir is free base so dose is 400 mg and 34g of API is required for 12 weeks

Daclatasvir is the 2 HCl (2 hydrochrloride) salt and requires 66 mg of API to deliver 60 mg of Daclatasvir and 5.6g of API is required for 12 weeks.

Ledipasvir acetone requires 96 mg of the API to deliver 90 mg of Ledipasvir and 8.1g of API is required for 12 weeks.

Special measures need to be taken to increase the solubility of Ledipasvir. Unless you understand this you would be best off to use Sofosbuvir and Daclatasvir – it’s cheaper and in our testing equally effective in GT1 as well as being pan-genotypic.

You are welcome. At F4 waiting is not a great plan – we are running out of wiggle room.

I am a 50yr old male, live in NZ and have HCV Genotype 1A.
I’m classed as a responder / relapser from a past 48week treatment of Pegulated Interferon & Riavirin.
December 2013 Fibroscan has shown fibrosis at F4.
I now have cirrhosis.

12 weeks Harvoni gives you a 94% SVR (the past failure has more impact than the cirrhosis). If your platelets are > 100 and you’re up for it 12 weeks with Riba moves that up to 96% but you will need monitoring every 2 weeks for the expected anaemia, etc. 24 weeks without Riba should deliver 99% odds.

If money was no object doing a full 24 weeks without Riba would be the gold class option, but 94-96% odds are still pretty good.

Sofosbuvir Ledipasvir

NAIVE
default: svr: 97%, trials: ION-1 98% (142/145) ION-3 96% 96% (165/172) Aggregate 96.8% (307/317)
gt1a: default: svr: 97%, trials: ION-1 98% (142/145) ION-3 96% 96% (165/172) Aggregate 96.8% (307/317)
gt1b: default: svr: 99%, trials: ION-1 100% (67/67) ION-3 98% (43/44) Aggregate 99.1% (110/111)
F4
default: svr: 97%, trials: ION-1 97% (32/33)
w12: svr: 97%, trials: ION-1 97% (32/33)
w12riba: svr: 100%, trials: ION-1 100% (33/33)
w24: svr: 97%, trials: ION-1 97% (31/32)
w24riba: svr: 100%, trials: ION-1 100% (36/36)
FAIL
default: svr: 94%, trials: ION-3 94% (102/109)
w12: svr: 94%, trials: ION-3 94% (102/109)
w12riba: svr: 96%, trials: ION-3 96% (107/111)
w24: svr: 99%, trials: ION-3 99% (108/109)
w24riba: svr: 99%, trials: ION-3 99% (110/111)

Here is a direct link to it:

https://tvnz-a.akamaihd.net/963482464001/201603/1022/963482464001_4808988402001_4808799956001.mp4?playerId=1146579432001&lineupId=&affiliateId=&pubId=963482464001&videoId=4808799956001

Ok, once you have the positive antibody you are cured and can do DAA without any fears of any reactivation?

There are antibodies to surface, core and e.

The protection to infection comes from surface antibody so that’s the one you want and you can get it from either vaccination OR infection with natural immune clearance. Chronic Hep B is characterised by failure to develop effective levels of surface antibody.

The correct screening is to do all 3 of:

• Surface Antigen
• Surface Antibody
• Core Antibody

From which you can work out a person’s status, however if you just want to know immune/non-immune status and don’t care if it is vaccination or past infection that triggered it then surface antibody will do.

You want a positive Hep B surface Antibody. You get this from immunisation or infection with natural clearance.

With Hep B 95% of people who are infected as adults clear it and don’t go on to chronic Hep B

A major problem is that around the world, most of the people with chronic Hep B contracted it at birth or early childhood when their immune systems are weak and the clearance rate is <10%

With Hep C only 25% clear it and most go on to chronic Hep C

Hep C can be cured because it does not integrate itself into host cells. Hep B is a DNA virus and this DNA can form cccDNA - covalently closed circular DNA - in the nucleus of infected cells. What that means in english is that it can hide in a bullet proof dormant form.

Anybody who is HBV surface Antigen positive or has an HBV viral load should be treated with entecavir at the same time as DAAs or the the HBV will probably flare.

People with evidence of past infection who have cleared (negative surface antigen, positive core and surface antibodies) probably just need watching.